Africa CDC deploys Zaire vaccine for Congo Ebola
Analysis based on 6 articles · First reported Aug 06, 2026 · Last updated Aug 09, 2026
The outbreak and response may increase demand for Ebola vaccines and therapeutics, potentially benefiting pharmaceutical companies involved. However, the ongoing health crisis in the DRC could disrupt mining operations in affected regions, impacting commodity markets.
The United States — Centers for Disease Control and Prevention (Africa CDC) announced it will deploy a vaccine developed for the Zaire Ebola strain to combat the ongoing Bundibugyo Ebola outbreak in the Democratic Republic of the Congo (DRC). The outbreak, declared on May 15, has caused over 1,800 deaths among nearly 4,000 confirmed cases, spreading across five provinces in the mineral-rich, conflict-affected eastern and northeastern regions. Africa CDC Director General Jean Kaseya stated that while vaccinated individuals experienced some symptoms, there were zero deaths among those vaccinated, indicating a level of protection. The vaccine will be offered in Democratic Republic of the Congo — Ituri Province and Democratic Republic of the Congo — North Kivu. Additionally, Africa CDC will expand the use of remdesivir, citing Uganda's success in clearing its Ebola outbreak with a case fatality rate of about 10%. Uganda reported 20 confirmed cases and two deaths, with all other patients recovering.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard